Search results for “site:ncbi.nlm.nih.gov”

Page 42 of about 437 results

ncbi.nlm.nih.gov pubmed › 34545805

SARS-CoV-2 Delta Variant among Asiatic Lions, India

In May 2021, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in Asiatic lions in a zoological park in India. Sequence and phylogenetic analyses showed the SARS-CoV-2 strains were the B.1.617.2 (Delta) variant. To...

ncbi.nlm.nih.gov pubmed › 34641339

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

The COVID-19 pandemic needs no introduction at present. Only a few treatments are available for this disease, including remdesivir and favipiravir. Accordingly, the pharmaceutical industry is striving to develop new treatments for...

ncbi.nlm.nih.gov pubmed › 34713179

Data and Digital Solutions to Support Surveillance Strategies in the Context of the COVID-19 Pandemic

<span><b>Background:</b> In order to prevent spread and improve control of infectious diseases, public health experts need to closely monitor human and animal populations. Infectious disease surveillance is an established, routine data...

ncbi.nlm.nih.gov pubmed › 34796309

Purtscher-like retinopathy in a patient with COVID-19 and disseminated intravascular coagulation

While several cases of central retinal artery and vein occlusion have been described in COVID-19 patients thus far, there has not been any reported cases of Purtscher-like retinopathy. To the best of our knowledge, this is the first case...

ncbi.nlm.nih.gov pubmed › 34914670

SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021

A new variant of SARS-CoV-2 (the virus that causes COVID-19), B.1.1.529 (Omicron) (1), was first reported to the World Health Organization (WHO) by South Africa on November 24, 2021. Omicron has numerous mutations with potential to...

ncbi.nlm.nih.gov pubmed › 34937145

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo. (Funded by Gilead...

ncbi.nlm.nih.gov pubmed › 34957469

SARS-CoV-2 Omicron variant: Characteristics and prevention

Coronavirus disease 2019 (COVID-19) has brought about a great threat to global public health. Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.1.529 has been reported in South Africa and induced a...

ncbi.nlm.nih.gov pubmed › 34960795

First Detection of SARS-CoV-2 Delta (B.1.617.2) Variant of Concern in a Dog with Clinical Signs in Spain

Several cases of naturally infected dogs with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported despite the apparently low susceptibility of this species. Here, we document the first reported case of infection...

ncbi.nlm.nih.gov pubmed › 35128398

Rapid vigilance and episodic memory decrements in COVID-19 survivors

Recent studies indicate that COVID-19 infection can lead to serious neurological consequences in a small percentage of individuals. However, in the months following acute illness, many more suffer from fatigue, low motivation, disturbed...

Try “site:ncbi.nlm.nih.gov” on: Marginalia · Mojeek · Wiby · DuckDuckGo · Bing · Google · Wikipedia · Internet Archive